8:00 am
Networking & Registration

8:25 am Chair’s Opening Remarks

Discovering Emerging Therapeutic Approaches & Treatment Strategies for CNS Diseases

8:30 am Exploring CNS Application of Protein Degraders to Determine Whether They Can be Utilized in a Selective Manner to Minimize Side Effects & Maximize Therapeutic Outcome

  • Beth Hoffman Founder, President & Chief Executive Officer, Origami Therapeutics


  • Deep diving into targeted protein degraders (TPDs) from neurodegenerative therapeutic perspective
  • Exploring the use of TPDs to minimize side effects and maximize therapeutic outcome
  • Deep diving into the future of TPDs in CNS disorders to determine their impact on the CNS therapeutic landscape

9:00 am Weaponizing the Microbiome Against Alzheimer’s Disease

  • George Tetz Chief Executive Officer, CLS Therapeutics & The Human Microbiology Institute


  • Investigating Alzheimer’s disease in the context of the microbiome: what do biopharma need to know?
  • Analyzing how microbial DNAs involvement in Alzheimer’s disease can be exploited as a treatment strategy against it
  • Revealing how DNA of some species triggers protein misfolding and learning how this influences Alzheimer’s development and progression

9:30 am Metabolic Dysfunction in Neurodegenerative Disorders: Spotlight on Parkinson’s, Huntington’s & Alzheimer’s


  • Understanding the impact of brain energy metabolism on health and disease
  • Exploring the advantages and disadvantages of metabolic interventions in CNS diseases
  • Discovering the power of ketogenic therapies can be harnessed against Huntington’s, Alzheimer’s & Parkinson’s

10:00 am
Speed Networking


This session is a great opportunity to introduce yourself to the attendees that you would like to have more in depth conversations with. Get
face-to-face, peer-to-peer time with pioneering minds dedicated to neurodegenerative drug development research to establish meaningful business relationships

10:45 am
Morning Break & Networking

Spotlight on Drug Development for Parkinson’s Disease

11:00 am Deep Diving into Therapeutic Targeting of the DJ-1 Protein for the Treatment of Parkinson’s Disease

  • Gergely Toth Chief Executive Officer & Chief Scientific Officer, Cantabio


  • Analyzing the link between oxidation and aggregation of DJ-1 and its loss of function as relevant to the onset of familial and sporadic
    Parkinson’s disease
  • Comprehensively evaluating various oxidized states of DJ-1 as biomarkers for Parkinson’s disease using novel ELISAs.
  • Learning how to target DJ-1 by novel pharmacological chaperones as a therapeutic approach for Parkinson’s disease

11:30 am Enhancing Lysosomal Function as a Therapeutic Strategy for Parkinson’s Disease

  • Magdalene Moran President & Chief Scientific Officer, Carraway Therapeutics


  • Investigating lysosomal dysfunction in neurodegenerative diseases and what this means from a drug development perspective
  • Exploring activating TRPML1 as potential treatment for GBA-PD
  • Looking through the crystal ball: Outlining future Caraway directions

12:00 pm Showcasing LRRK2 Inhibitors as Treatment for Parkinson’s Disease

  • Ross Jeggo Global Head of Neuroscience & Immuno-Inflammation Therapeutic Aria, Servier


  • Exploring the role of LRRK2 in the pathophysiology of Parkinson’s disease
  • Uncovering case studies which showcase the benefit of therapeutic approaches to inhibit LRRK2
  • Revealing how new small molecule inhibitors of LRRK2 can be used to treat Parkinson’s disease

12:30 pm
Lunch & Networking

Discovery & Translational Track

Streamlining Target Discovery

1:30 pm Learning How to Integrate Information on Cellular Communication & Pathways for a Multi-Omic Approach to Target Identification


  • Hearing how to use fluid biomarkers for patient stratification demonstrates the current limitations of clinical disease classifications.
  • Understanding the urgent need to better understand causative mechanisms of CNS pathology, novel insights from bulk and single cell transcriptomic
  • Exploring reverse translation of clinical trial data; learning more from man than mouse

2:00 pm The New Target Journey: How to Progress from Target Identification & Illustrate Meaningful Effect in Pre-Clinical Models

  • Je Min Yoo Chief Technology, Officer, Biographene


  • Exploring the serendipitous discovery of the therapeutic candidate
  • Outlining the journey of advancement from discovery to in vitro & in vivo studies
  • Investigating expansion to further indications

2:30 pm Audience Discussion: Investigating How to Practically Apply the Latest Genetic Research for More Precise Target Discovery Every year exciting progress


Every year, exciting progress is made in understanding how genetics influences the development and progression in a plethora of neurodegenerative disease. How can the industry use this genetic research to design more effective therapeutic approaches against them? Join a small group of your peers at this focused audience discussion, to discuss your experience with using genetics to influence your target selection and therapeutic design. Leave with the knowledge you need to use genetics to strategically select optimal targets which align with your therapeutic approach in 2022 and beyond.

Late Translational & Early Clinical Track

Analyzing Key Clinical Trial Updates

1:30 pm Uncovering Bryostatin Targets Restoration of Synaptic Wiring Lost in Alzheimer’s Degeneration


  • Investigating actual cognitive improvement over baselines measured in initial placebo-controlled clinical trials
  • Hearing evidence for sustained benefit for weeks after drug regimens have been in trialled
  • Showcasing targets including synaptic growth factors, the apoptosis pathway, as well as amyloid and neurofibrillary tangles

2:00 pm From Concept to Clinic: Targeting the Nitric Oxide-Soluble Guanylate Cyclase-cGMP Pathway for Neurodegenerative Diseases

  • Chris Winrow Vice President & Head of Translational Medicine, Cyclerion


  • Unlocking the full therapeutic potential of the nitric oxide-soluble guanylate cyclase-cGMP signaling pathway in the brain
  • Demonstrating successful clinical translation of sGC stimulation for CNS drug development
  • Exploring the benefits of incorporating objective biomarkers in early clinical development

2:30 pm Versatile Therapeutic Intervention Approaches to Modulate Microglial Activity for the Treatment of Neurodegenerative Disease

  • Raj Ganesan Senior Director -Protein Engineering & Antibody Discovery Research, Alector


  • Hearing how the quest for therapeutic intervention to treat neurodegeneration has gained momentum with the emergence of a plethora of therapeutic modalities that can help harness novel biological insights.
  • Understanding opportunities and challenges in the therapeutic strategies to target microglial receptors such as TREM2, CD33 etc., and microglial Progranulin (PGRN), that have been strongly associated with an increased risk of developing Alzheimer’s disease.
  • Outlining versatile approaches that are being pursued to engage innate immune cells to alter the course of disease progression and have the potential to greatly expand the drug discovery toolbox and druggable targets

3:00 pm
Afternoon Break & Networking

The Beta Amyloid Revival & Beyond: A Deep Dive into Clinical Trials for Alzheimer’s Disease

3:30 pm ALZ-801 Phase 3 Program: Lessons & The Path Forward in Developing Targeted Therapies for Alzheimer’s Disease

  • Martin Tolar Founder, President & Chief Executive Officer, Alzheon


  • Highlighting the benefits of applying genomic stratification of patients for validation of biomarkers from target discovery to therapeutic development
  • Describing discovery of a novel molecular mechanism of action of ALZ- 801, which blocks formation of toxic amyloid oligomers associated with development and progression of Alzheimer’s disease
  • Reviewing development of ALZ-801, a Phase 3, first-in-class, small molecule oral inhibitor of amyloid aggregation and neurotoxicity
  • Emphasizing need for application of Precision Medicine approach in neurodegeneration, based on individual genetic and biological information to advance therapies with the greatest impact for patients

4:00 pm HOPE4MCI – Exploring Hippocampal Overactivity Prevention in the Elderly


  • Understanding how the production and deposition of amyloid is driven by neural activity
  • Investigating how the spread of tau along connectional pathways is driven by neural activity
  • Learning how HOPE4MCI (using AGB101) is the first trial to target heightenednhippocampal/MTL neural activity for a sufficient duration (78 weeks to assess change in progression using biomarkers alongside clinical/ cognitive outcomes for efficacy

4:30 pm Deep Diving into the Development of a PPAR Delta/Gamma Agonist T3D-959 for Alzheimer’s Disease


  • Understanding the PPAR rational in Alzheimer’s Disease
  • Revealing the latest pre-Clinical and early clinical data for T3D-959
  • Showcasing ongoing PIONEER Phase 2 Study with T3D-959

5:00 pm End of Day One